The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.
HealthDay News — The US Food and Drug Administration (FDA) has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback